Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

Approximately 6,000 participants 5 years of age and older will be enrolled in Lyme disease-endemic regions in Europe and the U.S. NEW YORK& SAINT-HERBLAIN, France--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN;...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials